Durata Therapeutics, Inc. Presents Results From Skin Lesion Measurement Study at IDWeek 2012

Published: Oct 19, 2012

SAN DIEGO--(BUSINESS WIRE)--Durata Therapeutics (NASDAQ: DRTX) today announced data from a multicenter, observational study related to the clinical development program of its lead product candidate, dalbavancin. The results demonstrate the reliability of the measurement tools deployed by Durata Therapeutics in its two ongoing, global, Phase 3 clinical trials for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria.

Back to news